(Q34605022)

3 August 2017

1 reference

title

Nonalcoholic Fatty liver disease and obesity (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

3 August 2017

0 references

0 references

1 reference

1 reference

Sherif Saadeh

1 reference

3 August 2017

publication date

1 February 2007

1 reference

Nutrition in Clinical Practice

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

1-10

1 reference

Nonalcoholic fatty liver disease

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Clinical hepatology: profile of an urban, hospital-based practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Nonalcoholic Steatohepatitis in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Selection and outcome of living donors for adult to adult right lobe transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

betaAR signaling required for diet-induced thermogenesis and obesity resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Is NASH underdiagnosed among African Americans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Sucrase-isomaltase is an adenosine 3',5'-cyclic monophosphate-dependent epithelial chloride channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Modulation of insulin activities by leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Focal manifestations of diffuse liver disease at MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

AGA technical review on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Hepatic ultrasonic changes in workers exposed to perchloroethylene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Exercise limitation in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Effect of weight reduction on hepatic abnormalities in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Effect on Hepatic Morphology of Treatment of Obesity by Fasting, Reducing Diets and Small-Bowel Bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Hepatic effects of dietary weight loss in morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Effects of the amount and intensity of exercise on plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Surgery for severe obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F011542650702200101

10.1177/011542650702200101

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference